An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors.
Phase of Trial: Phase I/II
Latest Information Update: 28 Jul 2016
At a glance
- Drugs CEP 9722 (Primary)
- Indications Breast cancer; Gastric cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Cephalon
- 18 Oct 2013 Planned End Date changed from 1 Aug 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 01 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.